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Objectives: Novel antibacterial strategies against Helicobacter pylori are needed because H. pylori strains are
acquiring resistance to antibiotics. We evaluated the efficacy of gentamicin-intercalated smectite hybrid
(S-GEN)-based treatment regimens in a murine model of H. pylori infection.
Methods: Two groups of 10 rats were administered either smectite or S-GEN to measure coverage of the gastric
mucosa. To evaluate anti-H. pylori efficacy, mice were divided into eight groups of 10 mice each given different
treatments, andH. pylori eradication was assessed by a Campylobacter-like organism (CLO) test andH. pylori PCR
of the gastric mucosa, and H. pylori antigen and H. pylori PCR analysis of mouse faeces. The levels of proinflam-
matory cytokines were examined.
Results: S-GEN was retained in the gastric mucosal layer with a .60% distribution ratio for up to 1 h, and the
S-GEN-based triple regimen decreased bacterial burden in vivo compared with that of untreated mice or mice
treated with other regimens. The cure rates in the CLO test and H. pylori PCR from gastric mucosa were
70%, 60%, 80%, 50%, 60% and 60% in Groups III–VIII, respectively. Those for H. pylori PCR in the faeces of
mice were 90% and 100% in Group III with standard therapy and Group V with triple therapy including S-GEN,
respectively. S-GEN triple therapy also reduced the levels of proinflammatory cytokines.
Conclusions: These results suggest that S-GEN is a promising and effective therapeutic agent for the treatment
of H. pylori infection.
Introduction
Helicobacter pylori is one of the most predominant bacterial patho-
gens in humans, colonizing the stomachs of nearly half of the global
population.H. pylori infection is responsible for most cases of inflam-
matory gastritis, peptic ulcer disease and gastric cancer in humans.1
Various attempts to develop preventive vaccines against H. pylori
have failed. Upon diagnosis, H. pylori infection is treated with con-
ventional antibiotic regimens. However, the success rate of these
treatments has been compromised by the drastic increase in
antimicrobial-resistant H. pylori strains.2 The prevalence of H. pylori
resistance to metronidazole, which is a key component of the triple-
therapy regimen, has increased to 40% in developed countries,
with a higher prevalence of90% in developing countries.3
The prevalence of MDR H. pylori strains is rapidly increasing;
hence, there is an alarming need to develop alternative and
effective antimicrobial agents. Among the promising candidates
are aminoglycosides, of which gentamicin, tobramycin and netil-
micin show high activity against H. pylori, with an MIC required to
inhibit 50% of bacteria (MIC50) of 0.125 mg/L.
4 However, aminogly-
cosides are polar, water-soluble compounds with very poor intesti-
nal membrane permeability, resulting in low oral bioavailability.5,6
Therefore, intravenous or intramuscular injections are required,
increasing the risk of adverse effects, such as nephrotoxicity and
ototoxicity, and increasing hospitalization-associated costs. Thus,
there are limitations when developing aminoglycosides as new
anti-H. pylori treatments.
Smectite clay, a type of layered aluminosilicate, is composed
of tetrahedral sheets of SiO4 units and octahedral sheets of
Al3! ions.7 It possesses hydrophilicity, high dispersibility in water
and cation exchange capacity.8 Therefore, smectite clays can
encapsulate various protonated and hydrophilic organic molecules
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into the interlayer space of the plane, making them good carriers
for hydrophilic drugs.9 In this study, a gentamicin-intercalated
smectite hybrid (S-GEN) was successfully synthesized. This should
prolong gentamicin’s gastric residence time, generating a local
therapeutic effect againstH. pyloriwithout adverse effects.
Thus, the study was aimed at comparing the therapeutic efficacy
of S-GEN and other regimens, including standard triple therapy,
using a mouse model of H. pylori infection. To assess host response
to S-GEN treatment, we examined the levels of proinflammatory
cytokines, including IL-8 and TNF-a, during the treatment.
Methods
Intercalation of gentamicin
Gentamicin solution (2 mg/mL) was prepared using United States
Pharmacopeia (USP)-grade gentamicin sulphate produced by Bio Basic Inc.
Ca-smectite was prepared by purifying bentonite from the Gampo area in
Korea. S-GEN was produced by mixing 250 mL of gentamicin solution per
gram of Ca-smectite, and stirring vigorously for 24 h. After mixing, the
hybrid solution was dialysed with 5 L of distilled water for 8 h at 50C,
which was repeated three or four times until sulphate ions could not be
detected with PbCl2. The hybrid powder was obtained by freeze-drying the
dialysed hybrid solution for 2–3 days. The amount of gentamicin released
from the hybrid was determined by a batch-release test, in which 25 mL of
pH 1.2 solution was added repeatedly to the same 100 mg of hybrid
powder. Gentamicin concentration from the supernatant was measured
using LC–MS. LC analyses were performed using the Thermo Scientific
ICS system. MS analysis was performed using a Thermo Scientific MSQ Plus
single-quadrupole mass spectrometer with electrospray ionization. The
total amount of gentamicin released within 1 h was determined to be
5.0 mg per 100 mg of the hybrid.
Ethics
The Institutional Animal Care and Use Committee at the National Center of
Efficacy Evaluation for the Development of Health Products Targeting
Digestive Disorders, Incheon, Korea, approved the animal procedures con-
ducted on rats.
Mouse experiments were reviewed and approved by the Institutional
Animal Care and Use Committee of Wonkwang University College of
Medicine. Mice were fed a standard laboratory diet with water ad libitum
and treated according to the guidelines and regulations for the use and
care of animals of Wonkwang University, Iksan, Korea.
Covering the gastric mucosa in rats
Seven-week-old male Sprague–Dawley rats (weighing 220 g+20%) were
purchased from Samtako Ltd., Osan, Korea, to test the coverage of the gas-
tric mucosa. The rats were fasted for 24 h before experiments. Two groups
of 10 rats were administered either smectite or S-GEN at 10 mL/kg
(150 mg/kg) and euthanized after 1 h. For analysing the covering efficiency
of the gastric mucosa, their stomachs were excised, cut along the greater
curvature, and pinned. The gastric distribution ratio was calculated using
the following formula:
Gastric distribution ratio %ð Þ ¼ Gastric distribution area ðcm2ÞGastric total area ðcm2Þ  100
The ratio and area were analysed using the Leica Application Suite
V4 (Leica Microsystems Ltd., Korea). The gastric distribution ratio was
expressed as mean (+SD).
Anti-H. pylori efficacy in vivo
Inoculation of experimental animals
Four-week-old male C57BL/6 mice were purchased from Japan SLC, Inc.,
Shizuoka, Japan, for anti-H. pylori assessments. Mice were 5 weeks of age
and weighed 18–20 g at the start of the experiments.
H. pylori SS1 was used for inoculation. The bacteria were maintained on
Brucella Blood Agar (Merck, Germany) at 37C under microaerobic condi-
tions (10% CO2, 85% N2 and 5% O2) for 72 h. For the in vivo anti-H. pylori
assessment, 80 mice were acclimatized for 1 week before the experiment.
After acclimatization, the animals were fasted for 12 h, and 70 were
infected with 0.5 mL of 2.0%109 cfu/mL H. pylori suspension, administered
intragastrically through oral gavage every 48 h, three times per week. The
inoculation day was considered day 0 and subsequent days as days 1–21. A
group of uninfected mice, serving as the normal control group, received an
equivalent volume of PBS and distilled water.
Distribution of animals
The mice were distributed into the following eight groups of 10 animals and
allowed to rest for 1 week after the last inoculation: Group I, normal group
with uninfected mice; Group II, no-treatment control group, received distilled
water; Group III, treated with amoxicillin (14.25 mg/kg), clarithromycin
(7.15 mg/kg) and a proton pump inhibitor (PPI, omeprazole was used in
all groups that received a PPI, 400lmol/kg), and served as a positive
control group; Group IV, treated with amoxicillin (14.25 mg/kg), gentamicin
(4 mg/kg) and PPI (400lmol/kg); Group V, treated with amoxicillin
(14.25 mg/kg), S-GEN (78 mg/kg) and PPI (400lmol/kg); Group VI, treated
with gentamicin (4 mg/kg) and PPI (400lmol/kg); Group VII, treated with S-
GEN (78 mg/kg) and PPI (400lmol/kg); and Group VIII, treated with amoxi-
cillin (14.25 mg/kg) and PPI (400lmol/kg). Treatments were administered
orally once daily for 7 consecutive days. To confirm the H. pylori serological
status of the infected mice, H. pylori immunoglobulin G (IgG) levels were
determined with an ELISA kit (Cusabio Biotech Co., USA) before treatment.
Bacterial identification
Twelve hours after the last administration, mice were euthanized and
stomachs were removed from their abdominal cavities. The gastric mucosa
from the pylorus was biopsied for the Campylobacter-like organism (CLO)
test and PCR for H. pylori. Additionally, 0.5 g of faeces per mouse was col-
lected from the rectum and colon, suspended in the same volume of dis-
tilled water and filtered forH. pylori antigen (Ag) detection and H. pylori PCR
in faeces.
CLO test
The gastric mucosal samples of the pyloric region were assayed with CLO
kits (Asan Pharmaceutical Co., Seoul, Korea) and incubated at 37C for 12 h
to examine urease activity. The reaction (colour change) was deemed neg-
ative when bright yellow or positive when dark red. The reaction score was
graded from 0 to 3 with 0"no colour change, 1" bright red, 2" light pur-
ple and 3"dark red.
H. pylori PCR of the gastric mucosa
H. pyloriDNA was prepared using the previously described bead beater/phenol
extraction method.10 A bacterial suspension was placed in a 2.0 mL screw-
cap microcentrifuge tube filled with 200lL (paced volume) of glass beads
(diameter, 0.1 mm; Biospec Products, Bartlesville, OK, USA) and 200lL of phe-
nol:chloroform:isoamyl alcohol (50:49:1). The tube was oscillated on a Mini-
Bead Beater (Biospec Products) for 30 s and centrifuged (12000g for 15 min)
to separate the phases. The aqueous phase was subsequently transferred
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into another clean tube, and 10lL of 3 M sodium acetate and 250lL of ice-
cold absolute ethanol were added. To precipitate DNA, the mixture was kept
at #20C for 10 min. The harvested DNA pellets were dissolved in 60lL of
Tris–EDTA buffer (pH 8.0) and used as template DNA for PCR. PCR was per-
formed using AccuPower PCR Premix (Bioneer, Daejeon, Korea). After an initial
denaturation/activation step (95C for 5 min), DNA (50 ng) was amplified in a
20lL volume for 35 cycles of denaturation (94C for 60 s), annealing
(62C for 60 s) and extension (72C for 90 s), using the following primers:
H. pylori-specific ureA and ureC, sense 50-TGATGCTCCACTACGCTGGA-30 and
antisense 50-GGGTATGCACGGTTACGAGT-30 (expected product 265 bp),11 and
GAPDH, sense 50-TGGGGTGATGCTGGTGCTG-AG-30 and antisense 50-GGTTTCTC
CAGGCGGCATGTC-30 (expected product 497 bp).12 The PCR products were
analysed by electrophoresis in 1.5% agarose gels.
H. pylori antigen in mouse faeces
The H. pylori antigen was evaluated using the commercially available SD
Bioline H. pylori Ag kit (Standard Diagnostics, Inc.) according to the manu-
facturer’s instructions. Specimens (250 mg) were incubated with a diluent
solution at room temperature for 30 min and then 100lL was placed in
the H. pylori Ag examination device. The results were checked 15 min
later. A single red line indicated a negative and a double red line indicated a
positiveH. pylori result.13
H. pylori PCR of mouse faeces
Genomic DNA from stool specimens was extracted using the AccuPrep
Stool DNA Extraction Kit (Bioneer, Daejeon, Korea) according to the manu-
facturer’s instructions.14 A set of primers (sense 50-TGATGCT
CCACTACGCTGGA-30 and antisense, 50-GGGTATGCACGGTTACGAGT-30) was
used to amplify H. pylori-specific ureA and ureC (265 bp).11 Template DNA
(50 ng) and 20 pmol of each primer were added to a PCR mixture tube con-
taining 1 U of Taq DNA polymerase, 250lM each deoxynucleoside triphos-
phate, 50 mM Tris–HCl (pH 8.3), 40 mM KCl, 1.5 mM MgCl2 and the gel
loading dye. The volume was adjusted to 20lL with distilled water. After
initial denaturation at 95C for 5 min, the reaction mixture was subjected to
35 amplification cycles (60 s at 94C, 60 s at 62C and 90 s at 72C), fol-
lowed by a 10 min extension at 72C (GeneAmp 9700, Perkin Elmer, USA).
The PCR products were electrophoresed on 1.5% agarose gel.15
Quantification of inflammatory cytokines
Plasma was obtained for IL-8 and TNF-a assays on day 21 by the insertion
of a heparinized microhaematocrit tube into the ophthalmic venous plexus
of the mice. Plasma IL-8 and TNF-a levels were measured using mouse
ELISA kits (R&D Systems, Minneapolis, MN, USA).
Statistical analysis
Data are presented as means+ SE, and groups were compared using the
non-parametric Mann–Whitney test. We obtained 95% CIs for the detec-
tion rate using the MINITAB statistical software program (Minitab Inc., PA,
USA). If the 95% CIs of two values did not overlap, they were considered sig-
nificantly different. A P value ,0.05 was considered statistically significant.
Results were analysed using the Statistics Package for Social Science (SPSS
12.0 for Windows; SPSS Inc., Chicago, IL, USA).
Results
Coverage of the gastric mucous layer in rats
We chose the experimental conditions of 10 mL/kg (150 mg/kg)
and euthanized the experimental rats 1 h after oral administration,
considering the drug release time from the hybrid. S-GEN showed
a 60.2% (+14.3%) distribution ratio.
In vivo anti-H. pylori assessment
To evaluate the in vivo therapeutic efficacy of S-GEN against
H. pylori, we established the H. pylori infection model (Figure 1).
Furthermore, to confirm H. pylori infection, H. pylori IgG levels were
determined before and after treatment (Table 1).
CLO test and H. pylori PCR of gastric mucosa
Repeated intragastric inoculation ofH. pylori in mice produced a posi-
tive reaction (red colour) in the CLO test of the gastric mucosa
(Table 2). The cure rates for gastric mucosa (100#positive reactions)
were 70%, 60%, 80%, 50%, 60% and 60% in Groups III–VIII, respec-
tively. The Group V CLO score was the lowest among the H. pylori-
infected groups and was significantly lower than that of Group II.
The PCR products of H. pylori-specific ureA and ureC (265 bp)
were electrophoresed on 1.5% agarose gel, and visualized
(Figure S1, available as Supplementary data at JAC Online). The
cure rates were identical to those determined by the CLO test.
H. pylori antigen and PCR in faeces of mice
We used a stool antigen kit to detect H. pylori in faeces. We consis-
tently observed positive results in Group II and negative results in
the other groups.
H. pylori PCR was conducted to evaluate therapeutic effects in
H. pylori-infected mice (Table 3). The cure rates were 90% and
100%, respectively, in Group III (standard therapy) and Group V
(therapy with amoxicillin/S-GEN/PPI).
Quantification of inflammatory cytokines
To determine whether anti-H. pylori treatment, including S-GEN,
influences the production of cytokines, plasma concentrations of
inflammatory cytokines were measured in the mice (Table 4).
The levels of IL-8 and TNF-a in the treatment groups were signifi-
cantly lower than those in Group II (Table 4). The plasma levels of IL-
8 and TNF-a in Group V were the lowest among treatment groups.
Discussion
H. pylori is a Gram-negative microaerophilic helical bacillus that
affects the gastric mucosa and can be found attached to epithelial
cells of the human stomach.16 Approximately 50% of the world
population is H. pylori positive, with the developing countries hav-
ing a prevalence of 80%–90% and industrialized countries having
a prevalence of 35%–40%.17 Quadruple regimens are used as sal-
vage therapy when the standard, triple therapy regimen fails.18
Drug-resistant H. pylori strains are the most common cause of
treatment failure.19 In the present study, we evaluated the anti-
H. pylori efficacy of S-GEN in a mouse model. Our results demon-
strated significantly improved antimicrobial efficacy of S-GEN in
reducing theH. pylori load in mouse stomachs compared with that
of other treatment regimens, including triple therapy, the current
worldwide standard forH. pylori treatment.
Smectite is a phyllosilicate mineral composed of two sheets of
(Si,Al)O4 tetrahedra and one sheet of (Mg,Fe,Al)O4(OH)2 edge-
sharing octahedra, which form a sandwich-shaped structure
where one octahedral sheet is inserted between two tetrahedral
sheets. Isomorphous substitutions of Al for Si in the tetrahedral
Jeong et al.
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sheet and Mg for Al and Fe3! in the octahedral sheet induce a neg-
ative charge that causes the interlayer to be an active cation-
exchange site, indicating that smectite could be used as a
drug carrier.7,20 Therefore, smectite’s use as a drug delivery vehicle
has attracted great interest recently, and various studies
have reported different drug-intercalated smectite hybrids for
controlled delivery and release of drugs, including donepezil,21 lin-
comycin,22 chlorhexidine acetate23 and tetracycline.24,25
Evaluation of the in vitro activity of some aminoglycosides found
that they might serve as alternative agents in combination therapy
regimens.4 Of the aminoglycosides tested, the most active were
gentamicin, tobramycin and netilmicin, with MIC90 and MIC50
Acclimation
Male C57BL/6 mice
(4-week-old)
1st week
1st 2nd 3rd
2nd week
Maintenance period Test article, daily, po
3rd week
Sacrifice
H. pylori infection
H. pylori IgG ELISA
Group assignment
H. pylori IgG ELISA
recheck
Figure 1. Anti-H. pylori efficacy in vivo. The study protocol, including H. pylori inoculation and infection development in C57BL/6 mice, followed by
the treatments.
Table 1. Plasma concentration of H. pylori IgG in each group
Group
Inoculation
N
H. pylori IgG concentration
H. pylori infection treatment before treatment after treatment
I no DW 10 0.26+0.01 0.25+0.00**
II yes DW 10
0.58+0.05a*
0.74+0.01
III yes AMX!CLR! PPI 10 0.33+0.01**
IV yes AMX!GEN! PPI 10 0.35+0.01**
V yes AMX! S-GEN! PPI 10 0.32+0.01**
VI yes GEN! PPI 10 0.40+0.01**
VII yes S-GEN! PPI 10 0.34+0.01**
VIII yes AMX! PPI 10
3
77777777775
0.35+0.01**
DW, distilled water; AMX, amoxicillin; CLR, clarithromycin; GEN, gentamicin.
aData are expressed as means+ SE of 70 infected mice (Groups II–VIII).
*Significantly different from Group I (P,0.01).
**Significantly different from Group II (P,0.01).
Table 2. Results of CLO test with gastric mucosa after treatment
Groupa
Percentage of
animals negative by
CLO test (95% CIb) CLO score
I 100 (72.2–100.0) 0.0+0.0
II 0 (0.0–27.6) 3.0+0.0
III 70 (39.7–89.2)* 0.9+1.5*
IV 60 (31.2–83.1)* 1.2+1.6*
V 80 (49.0–94.3)* 0.6+1.3*
VI 50 (23.7–76.3) 1.5+1.6
VII 60 (31.2–83.1)* 1.2+1.6*
VIII 60 (31.2–83.1)* 1.2+1.6*
aEach group consisted of 10 mice.
bIncidence percentage (95% CI) was calculated with the MiniTab
statistics program.
*Significantly different from Group II (P,0.05).
Table 3. PCR analysis of H. pylori in faeces after treatment
Groupa
Percentage of animals negative by
faeces PCR (95% CIb)
I 100 (72.2–100.0)
II 0 (0–27.6)
III 90 (60.0–98.2)*
IV 80 (49.0–94.3)*
V 100 (72.2–100.0)*
VI 70 (39.7–89.2)*
VII 80 (49.0–94.3)*
VIII 70 (39.7–89.2)*
aEach group consisted of 10 mice.
bIncidence percentage (95% CI) was calculated with the MiniTab
statistics program.
*Statistically significantly different from Group II (P,0.05).
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values of 0.25–0.5 and 0.125–1.00 mg/L, respectively.4 However,
aminoglycosides are very poorly absorbed when administered
orally, and must be given parenterally for systemic infections.26
Furthermore, the major limitation of the clinical use of aminoglyco-
sides continues to be concerns about nephrotoxicity and ototoxic-
ity.27 Evidence from previous reports has demonstrated a
correlation between the nephrotoxic effects of aminoglycosides
and the accumulation of these drugs in the kidney cortex.28,29
Therefore, we developed S-GEN and evaluated whether it could be
effective for the treatment ofH. pylori infection.
H. pylori mainly resides within the layer of adherent mucus
close to the epithelial surface.30 Therefore, for effective treatment,
S-GEN must cross the mucus layer and be retained on the stomach
wall. In this study, the S-GEN was well distributed on the distal gas-
tric wall; the observed 60.2% presence of S-GEN indicated effective
S-GEN retention for up to 1 h. This result suggests that S-GEN could
be used for direct eradication ofH. pylori.
In the results of the CLO tests and H. pylori PCR with gastric
mucosa after treatment, Group V had the highest cure rate (80%)
among the treated groups. Furthermore, the Group V CLO score
was the lowest score among treatment groups (0.6+1.3). Anti-
H. pylori efficacy was evident in Group V. In the case of the H. pylori
PCR test with faeces after treatment forH. pylori infection, negative
findings were consistently observed in Group V only. Therefore, the
superior anti-H. pylori activity conferred by the S-GEN triple therapy
can be explained by its direct killing effect and prolonged retention
in the gastric mucosa compared with that of the other regimens of
conventional antibiotics.
Interestingly, S-GEN-treated mice had significantly reduced
H. pylori-induced proinflammatory cytokines (IL-8 and TNF-a)
compared with H. pylori-infected but untreated mice. IL-8 attracts
neutrophils, thereby promoting inflammation,31 and TNF-a,
together with IL-1b, induces gastrin secretion, suggesting a role
for these cytokines in H. pylori-induced hypergastrinaemia and
inflammatory responses.32,33 The immune response to H. pylori
contributes to disease pathogenesis.34 Thus, reduction of the
proinflammatory response, as observed here, is expected to
reduce the inflammatory reaction responsible for perpetuating tis-
sue injury. Upon S-GEN treatment, an early clearance of coloniza-
tion and better anti-H. pylori effectiveness than that achieved with
other regimens could reduce gastric inflammation. However,
immunomodulatory properties of smectite itself in the tissue injury
should be confirmed by further research.
The current study has a limitation that needs to be addressed.
Tissue toxicity was not evaluated, limiting the information regard-
ing the effect of S-GEN on gastric mucosa. In the present study,
treatment with S-GEN had no effect on mouse body weight.
The safety of smectite by oral administration has been demon-
strated, and gentamicin was not absorbed through the gastric
mucosa. However, the safety of S-GEN with regard to the mucosal
layer should be confirmed by additional studies.
We demonstrated prolonged retention of S-GEN in the gastric
mucosal layer, and potent antimicrobial activity of S-GEN against
H. pylori. S-GEN treatment decreased the bacterial burden in vivo,
compared with untreated mice or mice treated with double or
triple therapy including PPI. In addition to its direct killing effect,
S-GEN inhibited proinflammatory cytokine production to help
reduce inflammatory responses. Overall, our data suggest that
S-GEN is a promising candidate as an anti-H. pylori agent.
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